Precision BioSciences, a clinical-stage gene editing company, presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in patients with chronic Hepatitis B. Data was presented at the International Coalition to Eliminate HBV (ICE-HBV) “HBV Cure Symposium” Meeting in Berlin, Germany. PBGENE-HBV is Precision’s wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to potentially cure chronic hepatitis B infection...